YolTech Kicks Off First-In-Class In Vivo Gene Editing Trial For TDT

Other Chinese Firms Build Presence In Field

YolTech’s early clinical stage in vivo gene editing therapy YOLT-204 may provide off-the-shelf treatment in transfusion dependent β-thalassemia without conditioning chemotherapy and HSCT.

Gene editing tool
YolTech Therapeutics' first-in-class in vivo gene editing therapy, YOLT-204, in transfusion dependent β-thalassemia recently entered clinical trial. (Shutterstock)
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from Clinical Trials

More from Focus On Asia